Autopsy verification of Encephalitozoon intestinalis (microsporidiosis) eradication following albendazole therapy.
Microsporidian infections are increasingly recognized as an important cause of morbidity for persons infected with the human immunodeficiency virus. Encephalitozoon (formerly Septata) intestinalis is a recently described microsporidian that causes intestinal and disseminated infections in severely immunocompromised patients with acquired immunodeficiency syndrome. Several studies suggest that albendazole is an effective therapy for E intestinalis infection. However, relapses of symptoms and reappearance of microsporidian spores in diagnostic specimens have been reported following treatment in some cases. Because these results are based on examination of feces or cytologic specimens with an inherent sampling bias, it would be ideal to have autopsy data on the complete tissue evaluation of major organ systems of patients who had antemortem E intestinalis infection treated with albendazole. This report describes an acquired immunodeficiency syndrome patient with diarrhea and wasting syndrome associated with E intestinalis infection. Treatment with albendazole produced relief of his clinical symptoms and eliminated microsporidian spores in his feces. Following his death from other causes, an autopsy was performed. Comprehensive microscopic examination of all major organs revealed no evidence of residual microsporidian infection, suggesting parasitologic cure of E intestinalis with albendazole. The postmortem finding of complete clearance of microsporidia from body tissues is significant for future albendazole treatment of patients infected with E intestinalis and provides strong support for the value of the autopsy in evaluating the therapeutic efficacy of antimicrobials in emerging infections.
Joste
N E
NE
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Rich
J D
JD
Busam
K J
KJ
Schwartz
D A
DA
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D015766:Albendazole / Q000627:therapeutic use*; D000871:Anthelmintics / Q000627:therapeutic use; D001344:Autopsy; D016890:Encephalitozoonosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D007422:Intestines / Q000469:parasitology / Q000473:pathology; D008297:Male; D016896:Treatment Outcome
D000871:Anthelmintics; D015766:Albendazole